NYSEAMERICAN:TRXCTransEnterix Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix.

TransEnterix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransEnterix.

TransEnterix, Inc. (NYSEAMERICAN:TRXC) announced its quarterly earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.41) EPS for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.12. The medical instruments supplier had revenue of $0.60 million for the quarter, compared to analysts' expectations of $0.54 million. View TransEnterix's earnings history.

1 Wall Street analysts have issued 1-year target prices for TransEnterix's stock. Their forecasts range from $1.00 to $1.00. On average, they expect TransEnterix's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 174.7% from the stock's current price. View analysts' price targets for TransEnterix.

News articles about TRXC stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TransEnterix earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about TransEnterix.

TransEnterix saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 2,160,000 shares, a decrease of 10.7% from the May 31st total of 2,420,000 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 5.0% of the shares of the company are short sold. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include Omega Diagnostics Group (ODX), Daxor (DXR), Daxor (DXR), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), Akers Biosciences (AKR), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), Ansell (ANSLF), ANSELL LTD/S (ANSLY) and Commerzbank (CZMWY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Opko Health (OPK).

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $0.36.

TransEnterix has a market capitalization of $18.87 million.

The official website for TransEnterix is www.transenterix.com.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.